Skip to main content
. Author manuscript; available in PMC: 2009 Jun 1.
Published in final edited form as: Biochim Biophys Acta. 2008 Feb 20;1783(6):1211–1219. doi: 10.1016/j.bbamcr.2008.01.032

Figure 4.

Figure 4

MEK-1/Erk pathway is involved in EP4 suppression by TGZ treatment. T98G cells were pretreated with or without 20 µM PD 98059 (MEK-1/Erk inhibitor), 10 µM SB 203580 (p38 MAPK inhibitor) or 100 nM Wortmannin (PI3-K inhibitor) prior to the addition of TGZ (20 µM) for 48h. EP4 expression was measured with Western blot analysis (A) and real-time RT-PCR (B). The bar graphs represent mean ± S.D. of EP4/Actin of three experiments, each in duplicate. *P<0.01, significant compared with TGZ.